International investigators, clinicians, and care researchers will come together online for AAIC 2020 to discuss the latest studies, theories, and discoveries that will help bring the world closer to breakthroughs in dementia science.
_________________________________________________________________________________________________________
Quanterix Product Theater Presentation:
Tatiana Plavina, PhD, Quanterix VP, Clinical Strategy
Take a deep dive into the new Simoa p-tau181 blood immunoassay and be among the first to learn about our newest multiplex neurology kit targeted for Alzheimer’s research!
Access Video On-Demand!
_________________________________________________________________________________________________________
Spotlight On Quanterix Posters And Presentation At This Year’s Event:
Tuesday, July 28, 2020
12:00 am – 11:59 pm EDT
Poster #43506
Development of an ultrasensitive multiplex assay for simultaneous detection of Aβ1-42, Aβ1-40, GFAP and NF-L in blood
Poster #41238
An ultrasensitive immunoassay for detection of p-tau181 in blood
Oral Presentation:
A biorepository for the in-depth validation of pre-analytical sample handling effects on novel blood-based biomarkers for Alzheimer’s disease: the first results.
Session Chatroom: 7:30 AM – 7:55 AM (US Central Time), July 28
_________________________________________________________________________________________________________
Listing Of Poster And Presentation Abstracts Featuring Simoa Technology At Aaic:
Serum neurofilament light and whole brain volume associate with machine-learning derived brain-predicted age in the British 1946 Birth Cohort.
Wagen, et al
Association between plasma neurofilament light chain levels and cognition in early Parkinson’s Disease
Yong, et al
CSF phosphorylated tau-217 is increased in Alzheimer’s and Creutzfeldt-Jakob diseases, and correlates with amyloid pathology
Emeršič, et al
Plasma biomarkers predict amyloid pathology in cognitively unimpaired individuals
den Braberm et al
Plasma-based biomarkers for Aβ and tau predict longitudinal brain atrophy in cognitively healthy elderly and in patients with Alzheimer’s disease
Leuzy, et al
Plasma phospho-tau181 in over 400 cognitively healthy 69 to 71-year-olds: associations with cerebral amyloid, structural imaging and cognition in the Insight 46 study
Keshavan, et al
Plasma Tau is Negatively Correlated with Frontal Lobe CBF in Hypertensive Adults on the AD Spectrum
Swinford, et al
Association of Plasma Abeta and Tau levels in relation to cognition and brain structure in a diverse community
DeCarli, et al
The effect of APOE ɛ4 in Alzheimer’s disease biomarkers in Down syndrome
Vilaplana, et al
Serum Neurofilament Light in memory clinic practice
Willemse, et al
Aging and sex impact plasma NFL and t-Tau trajectories in individuals at risk for Alzheimer’s disease
Baldacci, et al
Tracking neurodegeneration in frontotemporal dementia and Alzheimer’s disease: a comparative study of plasma Tau and neurofilament light chain
Illán-Gala, et al
Serum glial fibrillary acidic protein and neurofilament light as prognostic biomarkers for clinical progression in subjective cognitive decline: the SCIENCe project.
Verberk, et al
A biorepository for the in-depth validation of pre-analytical sample handling effects on novel blood-based biomarkers for Alzheimer’s disease: the first results.
Verberk, et al
1H-MRS signature in Alzheimer disease in Down syndrome.
Barroeta, et al
Level of plasma tau and depression, anxiety and worry in cognitively normal older adults
Hall, et al
Plasma levels of an N-terminal tau fragment are highly associated with future cognitive decline and neurodegeneration in clinically normal elderly
Chhatwal, et al
Association of plasma neurofilament light chain (pNfL) with neuroimaging markers of neurodegeneration and cerebrovascular disease
Chong, et al
Quantifying the synaptic vesicle-associated protein, VAMP2, to verify changes in cerebrospinal fluid in preclinical stages of Alzheimer’s disease
Goossens, et al
Plasma p-tau immunoassays, methodological aspects and clinical performance
Blennow, et al
BDNF-Met polymorphism on top of amyloid pathology predisposes for faster cognitive decline in cognitively normal elderly: the SCIENCe project.
van den Bosch, et al
Elevated plasma neurofilament light (NfL) is associated with incident Alzheimer’s disease and accelerated cognitive decline in adults with Down Syndrome
Dang, et al
Plasma biomarkers Aβ42, Aβ40, and tau in Down Syndrome Dementia.
Honig, et al
Serum neurofilament light level in the clinical diagnosis of Chinese patients with Alzheimer’s Disease
Chu, et al
Plasma Neurofilament Light Chain (NfL) is Differentially Associated with Neuropsychological Test Performance among Non-Hispanic Whites and Hispanic, Mexican Americans: An HABLE Study.
Petersen, et al
Anterolateral entorhinal cortical thinning as a biomarker for Alzheimer’s disease in Down syndrome
Sathishkumar, et al
Cerebrospinal fluid tau biomarkers in the prediction and concordance of neurofibrillary tangle and amyloid pathology
Ashton, et al
VAMP2 is a cerebrospinal fluid marker of selective hippocampal synapse loss and episodic memory performance in Alzheimer’s disease
Belbin, et al
Peripheral Neurofilament Light Chain (NFL) level Predicts the Two-year Outcome of Amnestic Mild Cognitive Impairment in Chinese Han Population
Zhao, et al
Evaluation of extracellular vesicles isolated from the cerebrospinal fluid and plasma from former national football League players at a risk for chronic traumatic encephalopathy
Muraoka, et al
A new biological assay of Aβ clearance – the Aβ mid domain immunoassay
Torsetnes, et al
Correlation between cerebrospinal fluid and blood neurofilament light protein: A systematic review and meta-analysis
von Widekind, et al
Pathological significance of neuron-derived EVs in Alzheimer’s disease and its potential as biomarkers
Kudo, et al
Potosaccharide treatment showed efficacy on hyperactivity, learning and memory and neurofilament light chain (NfL) plasma level in APPSwDI/NOS2-/- (CVN) mouse model of Alzheimer´s Disease.
Switzer, et al
Peripapillary retinal nerve fiber layer thickness measured using optical coherence tomography as a marker of Alzheimer’s disease
Wang, et al
An ultrasensitive immunoassay for detection of p-tau181 in blood
Chen, et al
Translational potential of mouse CSF biomarkers in Alzheimer’s disease – association of CSF neurogranin with tau, NFL and amyloid pathology in App knock-in mouse models
Smailovic, et al
Longitudinal plasma levels of Neurofilament light in Down syndrome: a multicenter study
Alcolea, et al
Peripheral Neurofilament Light Chain (NFL) level Predicts the Two-year Outcome of Amnestic Mild Cognitive Impairment in Chinese Han Population
Zhao, et al
Plasma neurofilament light chain levels reflect caregiver burden and social cognition measures in familial frontotemporal lobar degeneration (FTLD)
Heuer, et al
Associations between subjective cognitive decline (SCD) diagnosis and severity with plasma tau and NfL levels using SIMOA technology
Azad, et al
Latent disease models estimate symptom onset in familial frontotemporal lobar degeneration and enable novel designs for early-stage clinical trials
Staffaroni, et al
Fluid-Based Biomarkers to Facilitate Clinical Trial Execution and Interpretation
Zetterberg, et al
Plasma p-tau immunoassays, methodological aspects and clinical performance
Blennow, et al
Biomarkers and Trial-Ready Cohorts for Alzheimer’s disease Clinical Trials in the Down Syndrome Population
Fortea, et al
Gantnerumab In-depth Outcomes
Salloway, et al
Development of an ultrasensitive multiplex assay for simultaneous detection of Aβ1-42, Aβ1-40, GFAP and NF-L in blood
Shan, et al
Plasma phospho-tau in familial Alzheimer’s disease
O’Connor, et al
Quantification of tau phosphorylated at threonine 217 using a novel ultrasensitive immunoassay distinguishes Alzheimer’s disease from healthy controls
Kvartsberg, et al
Association between plasma neurofilament light chain levels and cognition in early Parkinson’s Disease
Yong, et al
Predicting development of AD clinical symptoms and their progression through a collection of novel plasma Aβ immunoassays
Liu, et al
Potosaccharide treatment showed efficacy on hyperactivity, learning and memory and neurofilament light chain (NfL) plasma level in APPSwDI/NOS2-/- (CVN) mouse model of Alzheimer´s Disease.
Switzer, et al
Plasma p-tau181 accurately predicts Alzheimer’s disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline
Rodriguez, et al
Quantification of Neurological Blood Based Biomarkers in Critically Ill Patients with COVID-19
Cooper, et al
AL001 restores CSF PGRN levels and normalizes disease-associated biomarkers in individuals with frontotemporal dementia due to heterozygous mutations in the progranulin gene
Haynes, et al
Ultrasensitive blood biomarkers to predict cognitive decline and diagnose Alzheimer’s disease in the absence of AT(N) classification as the reference standard
Simrén, et al
Evaluating Vascular Cognitive Impairment and Dementia Due to Small-Vessel Disease Using Plasma Levels of PLGF and VEGFA
Winder, et al